Parabilis Medicines CEO Mathai Mammen speaks about the biotech's record $670M IPO, its desmoid tumor pipeline and plans beyond oncology.
Parabilis Medicines cemented the largest biotech IPO in industry history on Wednesday with its $670 million debut on the Nasdaq.
But the Cambridge, MA-based drug …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in…
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the…
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted…
Parabilis Medicines, the decade-old and well-funded
Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 million…
